Paul Kim – Principal, Kendall Square Policy Strategies
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Address: Tour Franklin
100/101 Quartier Boieldieu
La Défense 8
Tour Franklin 100/101 La Défense 8 Quartier Boieldieu 92042 Paris la Défense Cedex,France
Tel: +33 (01) 70 36 03 00
Web: https://www.cipclub.org/Referentiel/
CIP, in accordance with the 1901 French law of associations, contributes to improved circulation of products and information relating to the Public Healthcare System. It works with manufacturers, pharmacists in hospitals and offices, agents, distributors and other representative organisations.
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Gala Díaz Langou, a senior analyst and executive director at Argentina’s premier think tank CIPPEC, assesses the country’s recent transformative journey under President Milei. Drawing on 25 years of institutional…
Carlos Ceinos, President & Co-Founder of Principia, leads a Puerto Rico-based consulting firm focused on automation, MES, project management, and validation for the biopharmaceutical industry. Since 2019, the company has…
Monica Bettencourt-Dias of the Gulbenkian Institute for Science highlights the IGC’s pioneering role in biological sciences, supporting scientists and innovators who have significantly contributed to the field globally for over…
MARBIO, a new vaccine manufacturing joint venture in Morocco, is the result of a partnership between the BAB banking consortium (Bank of Africa, Banque Centrale Populaire, and Attijariwafa Bank), Swedish…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
Thomas Eldered, CEO of Sweden’s largest CDMO Recipharm, founded the company together with his business partner in 1995. Since becoming a public company in 2014, he highlights how this changed…
Carlos Ceinos, president of Puerto Rican service provider Principia, highlights how his previous experience in big pharma helped him to successfully establish his business, dedicated to providing automation and IT…
Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Sasho Ganov, general manager at BB–NCIPD (BulBio), explains the role of the company in the national health system as the only state-owned enterprise in Bulgaria as well as shares his…
Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company…
The Country Head Commercial Business of Cipla Czech Republic reviews the challenges faced since Cipla began Czech operations two years ago, the company’s expertise in the respiratory segment, and how…
Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not…
Tania Zulu Holt, Associate Principal at McKinsey & Company elaborates on the current pressures on the South African healthcare system, discusses the importance of innovation and emphasizes the need for…
IMS Health helps clients reach the top of the mountain by providing them with the necessary intelligence to take actionable steps. Manuel Voll, Senior Principal for Northern Europe shares his…
The phasing out of fiscal incentives in 2006 has impacted the Puerto Rican economy as well as the life science arena. The president of DDD Group, a company offering fully…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
Raul Manlapig, Principal Managing Director of Arup, Philippines, talks about the current rapid growth of the country’s economy, how the company’s sustained presence in many countries around the world provides…
A lot of the opportunities and challenges in the pharma and healthcare sector of Romania depend on the overall Romanian business environment in the first place. How would you assess…
The French President declared that he intended to make France the most welcoming and attractive place for the healthcare industry. Do you think this is possible? Can France be the…
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
See our Cookie Privacy Policy Here
